Biovaxys Technology Corp (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has secured a Japanese patent for their DPX™ platform, which facilitates strong immune responses through low-dose vaccine delivery. This advancement promises enhanced potency in their immunotherapeutics and therapeutic vaccines, targeting a range of diseases. Additionally, the company has filed for international patents to strengthen their global intellectual property rights and support their innovative immunotherapies pipeline.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
